ERBB2 and inflammatory breast carcinoma: Guided by the above findings, we hypothesized that the use of eribulin would result in a meaningful improvement in the pathologic complete response (pCR) rate in patients with HER2-negative IBC, a disease that exhibits some degree of resistance to chemotherapy [5].